Im Ghobrial

Bortezomib in the treatment of multiple myeloma

Bortezomib in the treatment of multiple myeloma , Bortezomib in the treatment of multiple myeloma , کتابخانه دیجیتال جندی شاپور اهواز

Molecular Pathways in Growth and Survival: Epigenomics

Epigenetics refers to those heritable changes in gene expression that are not induced by DNA sequence aberrations. One of the most well-defined epigenetic markers is histone acetylation which has been shown to be deregulated in clonal disorders, including both solid tumors and B-cell malignancies, such as Waldenstrom’s Macroglobulinemia (WM). Importantly, recent evidences have suggested that WM cells present with an aberrant histone acetylation status, and this may be due to deregulated microRNA profiling within the WM tumor clone, thus providing the preclinical support for using miRNA-based therapies in this disease.

B581 MicroRNA Regulate Growth and Angiogenesis in Multiple Myeloma

B570 Centrosomal Clustering: A Novel Therapeutic Target for Multiple Myeloma MS Raab, I Breitkreutz, B Rebacz, PJ Hayden, TO Larsen, MH Clausen, JH Fruehauf, H Goldschmidt, KC Anderson, A Kraemer Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; CCU Molecular Hematology/ Oncology, German Cancer Research Center, Heidelberg, Germany; BioCentrum, Technical University of Denmark, Kopenhagen, Denmark; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; National Center of Tumor Diseases, Dept. of Medicine, University of Heidelberg, Germany

A224 Lenalidomide, Bortezomib, and Dexamethasone Has Notable Activity in High-Risk First-Line Myeloma

A224 Lenalidomide, Bortezomib, and Dexamethasone Has Notable Activity in High-Risk First-Line Myeloma PG Richardson,1 S Lonial,1 A Jakubowiak,2 S Jagannath,3 N Raje,4 D Avigan,5 IM Ghobrial,6 R Schlossman,6 A Mazumder,3 NC Munshi,6 D Vesole,7 R Joyce,5 D Doss,6 D Warren,6 L Lunde,6 R Lukas,6 S Kaster,4 K Shea,4 C Delaney,5 M Lauria,5 C Mitsiades,6 T Hideshima,6 R Knight,8 DL Esseltine,9 KC Anderson6 1Winship Cancer Institute, Atlanta, GA; 2University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; 3St. Vincent’s Comprehensive Cancer Center, New York, NY; 4Massachusetts General Hospital, Boston, MA; 5Beth Israel Deaconess Medical Center, Boston, MA; 6Dana-Farber Cancer Institute, Boston, MA; 7Division of Hematology/Oncology, Loyola University Medical Center, Maywood, IL; 8Celgene, Inc., Summit, NJ; 9Millennium: The Takeda Oncology Company, Cambridge, MA, USA

A227 Lenalidomide, Bortezomib, and Dexamethasone Is Active in High-Risk Relapsed/Refractory Myeloma

A224 Lenalidomide, Bortezomib, and Dexamethasone Has Notable Activity in High-Risk First-Line Myeloma PG Richardson,1 S Lonial,1 A Jakubowiak,2 S Jagannath,3 N Raje,4 D Avigan,5 IM Ghobrial,6 R Schlossman,6 A Mazumder,3 NC Munshi,6 D Vesole,7 R Joyce,5 D Doss,6 D Warren,6 L Lunde,6 R Lukas,6 S Kaster,4 K Shea,4 C Delaney,5 M Lauria,5 C Mitsiades,6 T Hideshima,6 R Knight,8 DL Esseltine,9 KC Anderson6 1Winship Cancer Institute, Atlanta, GA; 2University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; 3St. Vincent’s Comprehensive Cancer Center, New York, NY; 4Massachusetts General Hospital, Boston, MA; 5Beth Israel Deaconess Medical Center, Boston, MA; 6Dana-Farber Cancer Institute, Boston, MA; 7Division of Hematology/Oncology, Loyola University Medical Center, Maywood, IL; 8Celgene, Inc., Summit, NJ; 9Millennium: The Takeda Oncology Company, Cambridge, MA, USA